[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600585":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":24,"responsibleParty":51,"collaborators":7,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":7,"enrollmentInfo":64,"targetDuration":7,"studyType":67,"phases":7,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":74,"whyStopped":7,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Montreal Heart Institute","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":12},"PET\u002FCT imaging with rubidium-82","PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.",[13,14],"Rubidium-82","PET\u002FCT",[16,22],{"name":17,"role":18,"phone":19,"phoneExt":20,"email":21},"Matthieu Pelletier-Galarneau, MD MSc","CONTACT","514-376-3330","4418","matthieu.pelletier-galarneau@icm-mhi.org",{"name":23,"role":18,"phone":7,"phoneExt":7,"email":7},"Pelletier-Galarneau",[25,40],{"facility":5,"status":7,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Montreal","Quebec","H1T 1C8","Canada","CA",{"type":32,"coordinates":33},"Point",[34,35],-73.58781,45.50884,{"lat":35,"lon":34},[38],{"name":39,"role":18,"phone":19,"phoneExt":20,"email":21},"Matthieu Pelletier-Galarneau, MD, MSc",{"facility":41,"status":7,"city":26,"state":27,"zip":42,"country":29,"countryCode":30,"cosmosGeoPoint":43,"geoPoint":45,"contacts":46},"Montreal Jewish General Hospital","H3T 1E2",{"type":32,"coordinates":44},[34,35],{"lat":35,"lon":34},[47],{"name":48,"role":18,"phone":49,"phoneExt":7,"email":50},"Gad Abikhzer, MD","514-340-8222","Gad.Abikhzer.med@ssss.gouv.qc.ca",{"type":52,"investigatorFullName":17,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Chief of the Nuclear Medicine Department","100600585","parathyroid-adenoma-detection-with-rubidium-82-imaging-100600585",false,"NCT07099404","Parathyroid Adenoma Detection With Rubidium-82 Imaging","Parathyroid Adenoma Detection With Rubidium Chloride Imaging: A Proof-of-Concept Study","PARAGON","Inclusion Criteria:\n\n1. Age ≥ 18y\n2. Ability to undergo imaging logistics\n3. Ability to provide informed consent\n4. Biochemical evidence of primary hyperparathyroidism\n5. Documented parathyroid adenoma on prior 18F-fluorocholine imaging\n\nExclusion Criteria:\n\n1. Normocalcemic primary hyperparathyroidism\n2. Breastfeeding or pregnancy\n3. Claustrophobia or inability to undergo imaging logistics\n4. Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study","ALL","18 Years",{"count":65,"type":66},20,"ESTIMATED","OBSERVATIONAL","Assess the uptake of rubidium-82 in parathyroid adenomas.",[70,71],"Parathyroid Adenomas","Hyperparathyroidism, Primary",[73],"Parathyroid adenomas, Rubidium-82","NOT_YET_RECRUITING","2025-08-18",{"date":77,"type":78},"2025-08-22","ACTUAL",{"date":80,"type":66},"2025-11",{"date":82,"type":66},"2028-09",{"name":17,"class":6},2]